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Abstract 
INTRODUCTION: Progress in understanding and management of vascular cognitive impairment (VCI) 
has been hampered by lack of consensus on diagnosis, reflecting the use of multiple different 
assessment protocols. A large multinational group of clinicians and researchers participated in a two-
phase Vascular Impairment of Cognition Classification Consensus study (VICCCS) to agree on 
principles (VICCCS-1) and protocols (VICCCS-2) for diagnosis of VCI. We present VICCCS-2.  
METHODS: We used VICCCS-1 principles and published diagnostic guidelines as points of reference 
for an online Delphi survey aimed at achieving consensus on clinical diagnosis of VCI.  
RESULTS: Six survey rounds comprising 65-79 participants agreed guidelines for diagnosis of VICCCS-
revised Mild and Major forms of VCI and endorsed the National Institute of Neurological Disorders-
Canadian Stroke Network (NINDS-CSN) neuropsychological assessment protocols and 
recommendations for imaging.  
DISCUSSION: VICCCS-2 suggests standardised use of NINDS-CSN recommendations on 
neuropsychological and imaging assessment for diagnosis of VCI so as to promote research 
collaboration. 
 
1. Introduction 
Since Hachinski et al [1] proposed the term multi-infarct dementia to describe dementia 
complicating ischaemic vascular disease, numerous other descriptors have been used to encompass 
the heterogeneous clinical and aetiological spectrum of cognitive impairment due to cerebrovascular 
disease (CVD). These include vascular dementia (VaD), vascular cognitive impairment (VCI), 
subcortical (ischaemic) vascular dementia, and vascular cognitive disorder, variably diagnosed 
according to multiple different guidelines or protocols [2-14], some agreed by national institutions or 
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research networks, e.g. Alzheimer’s Disease Diagnostic and Treatment Centers (ADDTC) [11], 
International Statistical Classification of Diseases, 10th Revision (ICD-10) [15], the National Institute 
of Neurological Disorders and Stroke–Association Internationale pour la Recherche et 
l’Enseignement en Neurosciences (NINDS-AIREN) [16], and Diagnostic and Statistical Manual of 
Mental Disorders (DSM) fourth and fifth editions [17, 18].  
 
Studies comparing some of these protocols have shown they are not readily interchangeable [19-
21]. After the commencement of the vascular impairment of cognition classification consensus study 
phase 1 (VICCCS-1), the American Heart Association/American Stroke Association (AHA/ASA) 
published a statement on vascular contributions to cognitive impairment and dementia [22]. This 
supported the use of assessment protocols previously published by NINDS-Canadian Stroke Network 
(CSN) [13]. There have been other recent contributions to this field from the International Society of 
Vascular Behavioural and Cognitive Disorders (VASCOG) [23] and in the fifth edition of the Diagnostic 
and Statistical Manual of Mental Disorders (DSM-5) [18]. The level of take up of these recent 
guidelines is still unclear. Only those published during VICCCS-1, before commencement of VICCCS-2, 
could be included for consideration in the present study [22, 24].  
 
The aim of VICCCS was to achieve broad international consensus on diagnosis of VCI, through 
participation of a large pool of international researchers and clinicians in an iterative survey using 
the Delphi approach. After two initial survey rounds, the study was separated into two phases: 
VICCCS-1, addressing key concepts in our understanding and terminology of cognitive impairment 
resulting from CVD [25], and VICCCS-2, focussing on the formulation of practical guidelines for 
diagnosis.  
 
VICCCS-1 achieved broad consensus on concepts of VCI. It supported the use of ‘Mild’ and ‘Major’ 
subdivisions of the severity of impairment, aligning with the revised terminology in DSM-5. VICCCS-1 
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participants concluded that attempts to separate Mild VCI into further subtypes according to 
affected cognitive domains were at present premature, but agreed that this should be an area of 
future research. VICCCS-1 agreed (see Figure 1, reproduced from [25]) that the Major forms of VCI 
(VaD) should be classified into 4 main subtypes: i) post-stroke dementia (PSD); ii) subcortical 
ischaemic vascular dementia (SIVaD); iii) multi-infarct (cortical) dementia (MID); and iv) mixed 
dementias (further subdivided according to additional neurodegenerative pathologies). Framed by 
these concepts, VICCCS-2 used the same Delphi methodology to agree diagnostic guidelines on 
determination of severity of VCI, and discrimination of subtypes. 
 
2. Methods 
Participants in VICCCS-1 [25] were invited to participate in VICCCS-2 (supplementary figure 1). While 
149 initially agreed to participate, only approximately half were active and committed respondents 
in three or more rounds, with low attrition and little variation in participation through the six rounds 
(65-79 participants in each round, a mean of 72). Of the active participants, 63-75% (mean 68%) 
were clinicians with direct involvement in clinical assessment or health service patient care. The 
remainder were non-clinical (i.e. supporting clinical work technically or otherwise, but not involved 
in clinical decision making, or predominantly involved in research). Individual round representation 
is provided in Supplementary table 1.  
 
2.1 Data collection 
We used the Delphi method, an iterative, multi-staged series of structured questionnaires with 
feedback of anonymised responses, and progressive refinement of questions to reach consensus 
[26]. The process was co-ordinated by a non-participating researcher (O.A.S). Anonymisation of 
responses facilitated free expression of opinion throughout the study. The feedback of summary 
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responses after each round informed subsequent questions and allowed unbiased evolution of 
group judgement. A threshold of two-thirds agreement was chosen to signify consensus [27] for 
issues refined iteratively through multiple rounds, as in VICCCS-1 [25]. For issues where this 
threshold was not reached, we present the summary data including the view that was most strongly 
supported. A summary of topics covered in each Delphi round is presented in Figure 2. The first two 
rounds were used to select from previous publications those diagnostic criteria deemed most 
valuable as a basis for further discussion. These provided main themes addressed in the four 
subsequent rounds (November 2012 – September 2013). Consensus views from topics addressed in 
VICCCS-1 were utilised in discussions. 
 
3. Results 
3.1 VICCCS foundation rounds and VICCCS-2 rounds 1 & 2  
In the two foundation rounds of VICCCS the consensus view (94% of respondents) was that none of 
the current diagnostic protocols was fully fit for purpose and that formulation of improved 
assessment criteria for VCI was a priority. Data from the foundation rounds, including the 
researcher-led [2, 6, 7, 11-14, 16, 28-30] and organisation-based diagnostic criteria/protocols that 
were critiqued by the participants, are provided as supplementary material. 
Participants selected their preferred criteria of the six presented (4 chosen as best starting points in 
VICCCS foundation rounds [6, 12, 13, 31] and 2 that were published during VICCCS-1 and could 
therefore be critiqued in VICCCS-2 [22, 24]). Of these six, the AHA/ASA Scientific Statement: vascular 
contributions to cognitive impairment and dementia [22], henceforth referred to as AHA/ASA, was 
the first preference of the highest proportion of respondents (41%), followed by NINDS-CSN [13] 
(25%). The AHA/ASA does not provide assessment protocols but refers to the recommendations 
made in the NINDS-CSN. These guidelines provided the basis for further discussion and elaboration. 
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According to most respondents (65%), VICCCS-2 aimed to provide a single set of diagnostic 
guidelines for clinical and research use. Agreed objectives were to develop a clear and efficient 
protocol that was simple to use and would yield readily interpretable results, allowing discrimination 
of VCI subtypes and severity.  
 
3.2 VICCCS-2 rounds 3-6 
3.2.1 Measure of severity - differentiating between Mild and Major VCI 
In VICCCS-1 round 4, participants considered the cognitive domains that needed assessment to 
measure the severity of VCI. These were reviewed in VICCCS-2 round 3, in which 94% agreed that the 
core domains for assessment should be executive function, attention, memory, language, and 
visuospatial function. The domains of learning, neuropsychiatry, and social cognition should be 
treated as optional, outside of the core assessment, unless and until there is stronger evidence for 
their inclusion. No other domains (including abstraction, agnosia, emotionality, praxis, and 
processing or psychomotor speed) were supported as core domains; for some, respondents thought 
there were insufficient tools for assessment (e.g. apraxia, that features in NINDS-CSN: 80% of 
respondents). 
 
Eighty-one percent of VICCCS-1 respondents felt the differentiation between Mild and Major VCI 
(VaD) should be based on the number of domains affected and that both IADL and ADL were 
necessary determinants. In VICCCS-2 round 3, a consensus (85%) definition was achieved for Mild 
VCI: impairment in at least one cognitive domain, and mild to no impairment in IADL/ADL, 
respectively (independent of the motor/sensory sequelae of the vascular event). In rounds 3 and 4 
several definitions were considered for Major VCI (VaD) but no overall majority was achieved for any 
one option. On further examination of the various choices, 71% had chosen a definition that 
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included the word “severe” and 73% had chosen an option with “at least ONE cognitive domain” 
(rather than “at least TWO cognitive domains”). These observations were presented to the 
participants in round 5, and they were asked to choose between the three most-favoured definitions 
from the previous round. There was 60% support for the Major VCI (VaD) definition: severe deficits 
in at least ONE cognitive domain (other deficits may be present in multiple domains) and severe 
disruption to IADL/ADL (independent of the motor/sensory sequelae of the vascular event). 
Consensus-level (67%) support was obtained for a definition requiring deficits in one rather than two 
cognitive domains and for inclusion of the descriptor “severe”. Those who did not support the 
mandatory inclusion of the descriptor “severe” highlighted the important issue of people with 
moderate cognitive impairment, and suggested the use of the term “significant” to allow greater 
clinical discretion and flexibility. The scenario of “… the case of the very bright patient whose 
functioning is severely compromised but still does ok on rudimentary cognitive assessment” was 
given as an illustrative example. 
 
On feedback of the results of round 5, participants were asked to consider an amendment of the 
definition of Major VCI (VaD) by substitution of “severe” with “significant”, i.e. clinically significant 
deficits in at least one cognitive domain (other deficits may be present in multiple domains) and 
severe disruption to IADL/ADL (independent of the motor/sensory sequelae of the vascular event). 
52% were in favour, and support for the most popular definition in round 5 – severe deficits in at 
least one cognitive domain (other deficits may be present in multiple domains) and severe 
disruption to IADL/ADL (independent of the motor/sensory sequelae of the vascular event) – had 
dropped to 34%. Although our pre-defined consensus level (67%) was not reached for any definition 
in either round, it was clear that some qualification of the severity of deficit in at least one cognitive 
domain was preferred. Therefore, the proposed definition (representing the majority view) for 
Major VCI (VaD) is: clinically significant deficits in at least one cognitive domain (other deficits may 
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be present in multiple domains) and severe disruption to IADL/ADL (independent of the 
motor/sensory sequelae of the vascular event). 
 
3.2.2 Clinical evaluation and time-frame for assessment 
Recommendations of the NINDS-CSN abbreviated clinical evaluation of VCI were strongly supported 
by round 3 respondents (86%). However, NINDS-CSN recommendations differ for research and 
clinical settings, and most round 2 respondents (77%) thought the priority should be to agree a core 
of assessments for both research and clinical use, with the option of additional assessments for local 
use in either a clinical or research context.  
It was agreed that a neuropsychological assessment protocol for use in a typical clinical diagnostic 
setting, noting time pressures and patient group capabilities, should take 60 minutes at most, 
although optional assessments could take additional time. The inclusion of all core items in the 
NINDS-CSN 60-minute protocol was supported by most round 3 respondents. Only the MMSE 
supplementary test was supported by most respondents (71%). Other supplemental tests -- Rey-
Osterrieth Complex Figure, Boston Naming Test and Digit Symbol-Coding Incidental Learning – did 
not achieve consensus support for inclusion. All core and supplementary items in the NINDS-CSN 30-
minute protocol were also supported (Table 1).  
 
3.2.3 The role of aphasia in diagnosis of VCI 
VICCCS-2 round 2 respondents agreed (72%) with the AHA/ASA statement on aphasia: "Severity of 
aphasia precludes proper cognitive assessment. However, patients with documented evidence of 
normal cognitive function (e.g. annual cognitive evaluations) before the clinical event that caused 
aphasia could be classified as having probable VaD/VaMCI."[22]. In round 4, respondents agreed 
(96%) on the qualifying sentence “that the assessment of IADL/ADL should be made where 
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possible”. 68% of round 4 participants felt that “probable Mild VCI or probable Major VCI” was the 
appropriate classification of cases with aphasia when imaging was available, and “possible” used in 
cases of aphasia when imaging was not available (90%). 
 
3.2.4 Those at risk of VCI 
One of the agreed principles in VICCCS-1 [25] was: “The new VCI construct recognises the 
importance of people who are at risk of VCI, however, their consideration should be contingent 
upon the presentation of a sustained level of impairment even if in a very mild form as opposed to 
impairment that can be transient or revert to normal levels”. Respondents agreed (96%) that people 
at risk of VCI should be given greater consideration for diagnosis if at least 6 months of sustained 
impairment is present. 88% also agreed that in those at risk of VCI, other potential causes of 
sustained impairment (e.g. depression or vitamin D deficiency), in addition to the already agreed 
exclusions from diagnosis (i.e. drug/alcohol abuse/dependence within 3 last months of first 
recognition of impairment or delirium) should have been excluded. Caregiver reporting (88%) and 
clinical observation (73%) were supported mechanisms to collect this information. Screening-type 
assessment (49%) and more detailed formal assessment (43%) were not supported by the majority.  
 
3.2.5 Possible and Probable terms in VCI and ‘Mixed dementias’ subgroup 
In the AHA/ASA, which served as a starting point to discuss the use of the terms ‘possible’ and 
‘probable’ VCI, only the categories of ‘possible’ VaD or VaMCI allowed the inclusion of other 
phenotypes (e.g. evidence of other neurodegenerative disorders). The AHA/ASA also does not 
provide separate diagnosis or allow delineation of further subgroups of patients (e.g. the co-
morbidities present in mixed dementias). In VICCCS-1 the consensus was that VCI should contain a 
standalone umbrella-like subgroup termed "mixed dementias". VICCCS-1 participants also agreed 
that this subgroup could comprise further groupings that included patients with specific 
combinations of phenotypes, each of which would be specifically named where possible (e.g. VCI-AD 
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if there is evidence of both VCI and AD). Furthermore, it was agreed that the order of the descriptive 
phenotypic terms relevant to patients should attempt to reflect the relative contribution of 
phenotypes present, i.e. AD-VCI, or VCI-AD, to the extent that discrimination was possible. 
On consideration of differences between the AHA/ASA and VICCCS-1, VICCCS-2 round 2 respondents 
agreed (92%) that the diagnostic guidelines should attempt to incorporate the VICCCS-proposed 
"mixed dementias" as a separate distinct diagnostic subgroup of Major VCI, and 'probable' or 
'possible' are to be used to differentiate the level of diagnostic evidence to help classify patients for 
both Major VCI (VaD) subgroups (81%) and Mild VCI (70%). 
 
3.2.6 Incorporating temporal relationships in VCI diagnosis  
In AHA/ASA a clear temporal relationship between a vascular event and onset of cognitive deficits is 
required for a ‘probable’ diagnosis. In VICCCS-1, the definition of PSD – an agreed subgroup of major 
VCI (VaD), required that cognitive decline develop within 6 months of stroke. However, temporal 
relationships were not discussed for other subtypes of VCI. In VICCCS-2, respondents thought that a 
clear temporal relationship between a vascular event and onset of cognitive deficits should not be 
an essential component for diagnosis of Mild VCI (77%), (SIVaD) (88%), mixed dementias (85%) or 
MID (74%).  
 
3.2.7 The role of imaging in VCI diagnosis 
In VICCCS-2 round 3, the consensus was that imaging evidence of CVD was essential for diagnosis of 
Major VCI (VaD) (86%) and Mild VCI (79%). In round 4, although most respondents felt the NINDS-
CSN recommendations were possible/appropriate in the respondents' clinical settings (75% MRI / 
81% CT), 93% thought that the "acceptable MRI measures" proposed in NINDS-CSN should be the 
core recommendation for imaging in clinical settings, and the “recommended MRI measures” 
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supported as additional measures for use in either clinical or research contexts (Table 2 and 3). 
Several respondents stated that CT might be insensitive or insufficient to detect small vessel disease 
or evaluate vascular status. The limitations of CT for VCI are also highlighted in NINDS-CSN. In round 
4, respondents agreed (93%) that MRI should be the gold-standard imaging for VCI and 90% agreed 
that CT should be used only if MRI were not available or deemed too costly. This would also apply to 
cases where MRI is contraindicated. A consensus (68%) was reached on the use of the term 
“possible” Mild VCI or Major VCI if neither MRI nor CT imaging were available. Yet 89% felt that 
"probable" was the appropriate diagnostic category if only CT imaging were available.  
Majority support (67%) was not reached for any of the other "future" imaging methods described in 
NINDS-CSN, and the consensus was that none of these is ready for inclusion in clinical diagnosis. 
 
A summary of VICCCS diagnosis guidelines is provided in Panel 1. 
 
4. Discussion 
VICCCS-2 has provided new consensus-based guidelines for diagnosis of Mild and Major VCI (VaD) as 
previously defined [25], with AHA/ASA and NINDS-CSN guidelines as reference points for discussions. 
Clinical evaluation and neuropsychological protocols in the NINDS-CSN were supported for use by 
VICCCS respondents. The "acceptable MRI measures" outlined in NINDS-CSN should be the core 
recommendation for imaging in clinical settings. In terms of assessing severity, VICCCS diagnosis 
guidelines specify deficits in at least 1 domain, with clinically significant cognitive deficits of sufficient 
severity (moderate to severe) and severe deficits in IADL/ADL differentiating Major from Mild forms. 
Patients with PSD, SIVaD, MID and mixed dementias should also be subcategorised and any 
comorbid neurodegenerative disease recorded. 
 
13 
 
4.1 Comparison of VICCCS with recently published guidelines  
VICCCS was conducted between 2010 and 2013, which coincided with the development of DSM-5 
and VASCOG criteria for Vascular Cognitive Disorders (VCD) [23]. VICCCS participants provided 
collective feedback on draft DSM-5 proposals that were made available prior to their finalisation, 
through a tailored survey developed (by O.A.S), in consultation with P.S. acting on behalf of the 
DSM-5 Neurocognitive Disorders Work Group. VICCCS respondents agreed that the Mild and Major 
terminologies proposed in DSM-5 were helpful and should be adopted in VICCCS. The VASCOG 
criteria are also aligned with DSM-5 [23].  
In terms of assessing severity, both AHA/ASA and VICCCS specify the same core domains for 
assessment. In VASCOG, visuoconstructional-perceptual ability, praxis-gnosis-body schema and 
social cognition are additionally tested. The definitions of Mild VCI are comparable; however, they 
are not sub-categorised in VICCCS as respondents felt more evidence was needed. The definition of 
major forms of VCI in VICCCS and VASCOG requires deficits in at least 1 domain, rather than 2 
domains as specified in AHA/ASA. Loss of independence in IADL is the threshold in VASCOG and 
DSM-5. In VICCCS-1, assessment of both IADL and ADL was deemed necessary to determine severity. 
Patients with PSD, SIVaD and MID are also subcategorised in VICCCS but not specified in AHA/ASA, 
although subtypes in VASCOG include cortical-subcortical and subcortical ischaemic. The AHA/ASA 
category of "Unstable VaMCI", for cases which revert to normal from VaMCI, was not supported by 
VICCCS respondents.  
One of the main differences between VICCCS and AHA/ASA is the VICCCS subcategorisation of 
patients with comorbid pathologies, seen to be important, under the umbrella term "mixed 
dementias" but with the types of pathologies specified. Improvements in the accuracy of this would 
be an important goal of any future operational diagnostic protocols, for which research into 
biomarkers may be helpful [32]. AHA/ASA does not delineate these subgroups of patients, with only 
the categories of ‘possible’ VaD or VaMCI allowing the inclusion of other phenotypes (e.g. evidence 
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of other neurodegenerative disorders). VASCOG criteria encompass categories of multiple causation, 
including VCD with concomitant AD (Major or Mild) and VCD with additional pathology: e.g. Lewy 
body disease. 
In VICCCS, the use of probable and possible terms is reserved for the strength of evidence to support 
diagnosis. One such example of supportive evidence is a clear temporal relationship between a 
vascular event and onset of cognitive deficits in PSD, which is differentiated from other forms of VCI 
by the onset of symptoms within six months of stroke. Another is the imaging of CVD. VICCCS 
respondents concluded that MRI is the gold standard for imaging. If CT were the only means 
available, only a ‘probable’ diagnosis could be made, and only a diagnosis of ‘possible’ if no imaging 
evidence were available. The recent STRIVE imaging criteria for small vessel disease [33] published 
after the completion of our study, aligned with VICCCS’ conceptualisation for SIVaD, warrant 
consideration in future validations of VICCCS-2. VICCCS supports and expands on the AHA/ASA 
guidance on patients with aphasia, in whom assessment of IADL/ADL should be made when possible, 
allowing diagnosis of ‘probable’ with imaging evidence or ‘possible’ without it.  
 
4.2 Limitations and future work 
The use of online Delphi surveys in VICCCS allowed flexible and confidential participation amongst an 
unprecedented number of international participants over an extended period [25, 26, 34]. The 
guidelines reflect considered opinion since there was little participant attrition between rounds (90-
97% of participants responding over rounds 2-6), reflecting sustained engagement, with most topics 
addressed over multiple rounds.  
 
Given the large number of respondents and their broad interdisciplinarity, it is noteworthy that we 
achieved consensus on most topics addressed in VICCCS. Reaching consensus was most challenging 
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for the definition of Major VCI (VaD), perhaps reflecting residual sensitivities associated with this 
diagnosis and associated implications for health and social care services. Consequently, specific 
thresholds of severity of impairment were not established. VICCCS-1 concluded that subtyping of 
Mild VCI may be worthwhile but required more research [25], a view supported in a recent study 
that highlighted the importance of harmonising neuropsychological test score levels for defining 
impairment [35]. Inclusion of defined thresholds of severity of impairment within the 
neuropsychological test battery and IADL/ADL may help to guide the differentiation of VCI subtypes 
in clinical settings. Support for the continued use of MMSE [36] may be surprising, given that MoCA 
[37] has been shown to be an equivalent or more sensitive test for the detection of VCI, ([38, 39], for 
example). It is noteworthy that only 23% of respondents indicated use of the NINDS-CSN 5-minute 
protocol, (see Supplementary information), whilst NINDS-CSN endorsed the full as well as the short 
MoCA. The use of biomarkers and advances in imaging criteria, [33, 40, 41], including the use of 
arterial spin labelling-MRI [42, 43], may refine the subtyping of Mild and Major VCI. Further work is 
needed on imaging protocols, including measurement of grey matter atrophy, cortical thinning or 
global atrophy in the context of suspected VCI [44, 45]. Given the presence of vascular pathologies in 
apparent cognitively normal elderly people, recent progress in establishing neuropathological 
diagnostic criteria for assessing the likelihood that CVD contributed to pre-mortem cognitive 
impairment [46] is likely to have an important role in the validation of future pre-mortem diagnostic 
approaches. Translational models and genetic studies may provide further insight into the 
pathological mechanisms and possible therapeutic targets for VCI [47]. A multimodal strategy for 
treatment of VCI, incorporating both non-pharmacological therapies, such as Transcranial Magnetic 
Stimulation ([48],for review], and pharmacological treatment, has been proposed [49]. 
 
 
5. Conclusions 
16 
 
We present a consensus-based set of guidelines for diagnosing VCI, supported by a large 
multinational group of researchers. VICCCS guidelines have drawn upon, critiqued, expanded and 
refined previous efforts. We hope that they will be widely adopted, to improve consistency in 
diagnosis and standardisation in VCI research. This would allow better comparison of findings across 
studies and facilitate large-scale collaborative research on a group of diseases that despite modest 
prevalence and considerable heterogeneity have major societal impact. 
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Legends 
Figure 1: Revised conceptualisation of VCI in VICCCS. Subtypes of VCI are divided according to level 
of VCI impairment into Mild VCI and Major VCI (VaD). Mild VCI is not further sub-divided at this time. 
Major VCI (VaD) is classified into 4 main subtypes as depicted. The 6 month temporal basis (denoted 
by the hashed box) for cognitive decline after stroke differentiates PSD from other forms of major 
VCI (VaD). Post stroke dementia (PSD) and Mixed dementias are further delineated if a comorbid 
neuropathology is present (N.B. AD and Dementia with Lewy bodies (DLB) are given as examples, 
with # denoting other possible combinations). Subcortical ischaemic vascular dementia or Multi-
infarct (cortical) dementia subtype cases with these specific types of dementia alone, however cases 
also presenting with any other neurodegenerative pathology would then be categorised as Mixed 
dementias (dashed arrows) according to the comorbidities present.  
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